Encourage high-quality priority research projects at the NIH on how medications affect pregnant and lactating women and their infants.

Kathy Castor · Florida · Democratic

policy impact 3.00 specificity 1.00 extraction confidence 96%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

It would modernize FDA regulations, raise awareness of research that includes pregnant and lactating women, and encourage high-quality priority research projects to be conducted at the NIH— to help ensure moms and babies stay safe and healthy.

Castor reintroduced legislation encouraging NIH priority research on medication effects for pregnant and lactating women and their infants.

Castor, Fitzpatrick, Underwood Reintroduce Bipartisan Legislation to Promote the Inclusion of Pregnant and Lactating Women in Clinical Research | U.S. Representative Kathy Castor
primary · press_release · model gpt-5.4-mini

Evidence

legacy_unverified · Source version not recorded · locator unknown

The caucus posted that, in FY25, more than $40 million was awarded through the NIH IMPROVE Initiative and that more than $142 million has been awarded through the initiative to date. The update says this NIH funding reflected grant requests from the caucus.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Recent official caucus reporting shows continued NIH-backed maternal-health research funding, but it does not show a medication-specific pregnancy/lactation research priority being delivered.

unresolved same_term

Black Maternal Health Caucus
secondary · model gpt-5.4-mini · confidence 62%

legacy_unverified · Source version not recorded · locator unknown

GovInfo bill text shows Rep. Kathy Castor introduced H.R. 8651 on May 4, 2026, and it was referred to House Energy and Commerce. Section 4 would require NIH, through NICHD, to carry out priority research projects on existing and new drugs prescribed for pregnant and lactating women and establish a prioritization process for funding those projects.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official bill text directly matches the promised NIH priority-research mechanism, but the action shown is introduction and committee referral, not enactment or NIH implementation. This is concrete Castor-led effort and supports partial credit rather than full delivery.

partial same_term A for effort

H.R. 8651 (IH) - Advancing Safe Medications for Moms and Babies Act of 2026
secondary · model gpt-5.5 · confidence 86%

legacy_unverified · Source version not recorded · locator unknown

Rep. Castor's office announced that she reintroduced H.R. 8651, the Advancing Safe Medications for Moms and Babies Act, to strengthen understanding of how medications affect pregnant and lactating women and infants, modernize FDA regulations, raise awareness of inclusive research, and encourage high-quality priority research projects at NIH.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Castor's official statement confirms renewed, candidate-led action on the exact medication-in-pregnancy/lactation research promise. It still describes proposed legislation, so it shows serious effort and partial movement, not completed delivery.

partial same_term A for effort

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): never. same_term A for effort

Castor materially advanced the promise by introducing H.R. 8651 in May 2026, which directly would require NIH priority research projects on medications used by pregnant and lactating women and infants. But the evidence shows introduction and committee referral only, with no enactment or NIH implementation of the promised medication-specific research priority. Under the instructions, this is a serious legislative attempt that did not deliver the promised outcome.

provider codex_cli · model gpt-5.5 · confidence 86%

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): partial. same_term

The available record shows meaningful movement in the promised policy area: NIH maternal-health research funding expanded through the IMPROVE Initiative, and caucus reporting says those grants reflected requests from the Black Maternal Health Caucus. But that does not establish the narrower promised outcome of a delivered NIH priority specifically focused on how medications affect pregnant and lactating women and their infants, nor does it show a clearly Castor-led enactment of that exact research agenda. Using federal candidate-credit standards, this supports partial credit for helping advance related NIH research funding, but not full delivery of the specific medication-research promise.

provider codex_cli · model gpt-5.4 · confidence 72%